to the brain
Moderator:
T. Stosic‑Opincal; Belgrade/RS
A‑049 16:00
A. Brain anatomy made easy
T.A. Yousry; London/UK (
[email protected])
The anatomy of the brain is often perceived as being complicated. Especially the cortex is
seen as an irregular arrangement of variable structures, which are difficult to differentiate
and to identify. We will review the overall subdivision of the brain into lobes and describe
their boundaries and their major gyri and sulci. We will then describe the location of spe-
cific functions. 1. Primary sensorimotor cortex: motor is located in the precentral gyrus,
sensory in the postcentral gyrus around the central sulcus (CS), hence the importance
of always correctly identifying the CS. We will present 4 interlocked methods to identify
the CS in the axial plane (a) knob, (b) lateral axial, (c) medial axial, (d) gyral/cortical
thickness and 3 to identify it in the sagittal plane (a) lateral sagittal, (b) hook, (c) medial
sagittal. 2. Primary auditory cortex (A1): centred at the postero-medial part of Heschl’s
gyrus (HG), we will present simple landmarks in each of the 3 planes: (a) axial: adhaesio
interthalamica, (b) sagittal: omega/heart shape of HG, (c) coronal: omega shape of HG.
3. Primary visual cortex (V1): Centred on the calcarine sulcus, we will discuss the char-
acteristic shape that allows the identification of this structure in all 3 planes. At the end
of this lecture, you will know the subdivision of the cortex; the methods and landmarks
necessary to identify the primary sensorimotor, speech, auditory, and visual areas.
Learning Objectives:
1. To recapitulate basic brain anatomy.
2. To be able to correlate different anatomic locations to CT and MR images.
3. To consolidate knowledge of the important landmarks for anatomic
structures on images.
A‑050 16:30
B. Pattern recognition and normal variants to know
M.M. Thurnher; Vienna/AT (
[email protected])
Magnetic resonance imaging (MRI) has undergone a rapid development in the
last decade with numerous new techniques. Nevertheless, pattern recognition of
brain lesions based on signal intensities on conventional MR sequences (T1- and
T2-weighted, FLAIR) is the first step in diagnostic “work up”. Good examples for
pattern recognition are lesions with T1-shortening (“bright” on T1WI) such as: fat
containing lesions (lipoma), melanoma, lesions with colloid content, calcifications,
and haemorrhagic metastatic lesions. T2-shortening (“dark” on T2WI) in enhanc-
ing lesions is suggestive of lymphoma and certain infections (tuberculosis, fungal
abscesses). Flow void (absence of signal) reflects high velocity flowing blood or
CSF, and will help in diagnosing vessel abnormalities and related pathologies. The
purpose of this lecture is to refresh knowledge on patterns and normal variants
useful for clinical practice. A simplified “pipeline” consisting of easy consecutive
steps will be introduced.
Learning Objectives:
1. To learn important normal variants of different structures and lesions in the
brain.
2. To learn about recognition patterns that might be helpful in suggesting the
most likely etiology of common brain lesions.
3. To consolidate the key imaging findings in different types of lesions and
normal variants.
A‑051 17:00
C. Clinical symptoms correlated to brain anatomy
M. Smits; Rotterdam/NL (
[email protected])
Diagnostic neuro-imaging heavily depends on a thorough understanding of brain
anatomy in relation to the brain’s function. Clinical neurological symptoms and
deficits not only give us an indication of the brain area(s) involved but may also
direct us towards the use of specific imaging techniques, such as diffusion tensor
imaging and tractography, as well as functional magnetic resonance imaging (fMRI).
Specific imaging findings, on the other hand, may direct clinical management in
a neurologically intact patient, such as the decision to resect a brain tumour in
or near an eloquent brain area. Again, specific imaging techniques may be used
Thursday
Postgraduate.Educational.Programme
A
S19
CB D E F G H
A‑056 16:05
Evaluation of tumour response to therapy: the role of radiology
M. O’Connell; Dublin/IE (
[email protected])
Evaluation of response to treatment allows an early assessment of tumour response
typically after 2-4 cycles of chemotherapy. This evaluation is most commonly per-
formed with PET/CT during therapy for high grade non-Hodgkin’s lymphoma. This
review presentation looks at the potential roles that CT, regional MRI and whole
body MRI do and could play in response evaluation from a radiology perspective.
The presenter is a radiologist who is clinical director of a medium volume PET/
CT centre. The talk focuses on discrepancies between CT and PET findings in
tumour response and on tumours or situations where CT is the primary modality
to determine tumour response. Potential roles for whole body MRI in response
evaluation and assessment of solid tumours by MRI are examined. At a general
level, the role of the radiologist as part of the multidisciplinary oncology meeting
(MDM), including when and where to use image-guided biopsy in response evalu-
ation and the use of RECIST versus PRECIST criteria is discussed. The aim of the
presentation is to outline the role of CT in tumour response evaluation in the era
of PET/CT and to explore potential roles particularly for whole body MRI in tumour
assessment. The presenter hopes to encourage radiologists to get fully involved
in MDM discussions regarding CT, MRI and PET/CT evaluation.
Learning Objectives:
1. To learn the standard method (tumour measurements) for the evaluation of
tumour response to treatment.
2. To understand the limits of international standard.
3. To become familiar with methods that provide functional or structural
information, like perfusion CTMR or DW-MRI.
A‑057 16:23
Evaluation of tumour response to therapy: the role of nuclear medicine
A. Chiti; Milan/IT (
[email protected])
The high costs and possible side effects of chemotherapy and radiation therapy
treatments favour the use of effective ways to monitor the treatment efficacy in
oncology. Molecular imaging demonstrated to be effective in evaluating the response
after and during the course of therapy, in order to assess chemo-sensitivity and
chemo-resistance of a particular neoplasm. The use of PET-CT in this setting can
vary from very sophisticated and complex quantitative evaluation to simple qualita-
tive analyses. In malignant lymphoma, international criteria for monitoring response
to therapy have recently been revised, and FDG now plays a central role in defining
tumour response. In a variety of solid tumours, studies have indicated that FDG
PET-CT may provide early and accurate assessment of tumour response, suggest-
ing that it could play a significant role in personalising the treatment of malignant
tumours. Performed during and after therapy for HL and aggressive NHL, FDG
PET results have a high prognostic value and correlate with survival. FDG PET
has been incorporated into revised response criteria for aggressive lymphomas,
and several ongoing trials are under way to investigate the value of treatment
adaptation based on early FDG PET results for HL and aggressive NHL. Many
technical aspects must be taken in consideration to avoid critical errors in evaluat-
ing response. From patient preparation to image acquisition a series of possible
pitfalls must be avoided. In the clinical practice, the most widely used parameter
is the SUV, which can improve the accuracy of qualitative image assessment in
many clinical settings.
Learning Objectives:
1. To understand why PET-CT can be used to assess tumour viability.
2. To become familiar with the principles of signal quantification and to discuss
its advantages and limits.
3. To learn about the incoming tracers that might enhance the role of PET-CT
in the evaluation of tumour response.
A‑058 16:41
Alzheimer’s disease: the role of radiology
J. Alvarez-Linera; Madrid/ES (
[email protected])
Neurobiological changes in Alzheimer’s disease (AD) occur in an stereotypical
pattern that begins in the medial temporal lobe (MTL) years before the clinical
manifestation (brain reserve). Brain atrophy is a marker of neurodegeneration that
reflects the neurobiological disorder and is correlated with the neuropsychological
changes at all stages of the disease. Other imaging markers may reflect changes
in microstructural (diffusion), functional (perfusion) or metabolic (MRS) domains
that would provide additional information but are awaiting wider validation. In the
early stages of AD, the most effective MRI markers are those that reveal atrophy
in MTL, particularly the measures of the hippocampus. The MTL atrophy mea-
the required conditions in whom they may be successfully used, and how these
techniques could be implemented in the daily clinical practice.
Learning Objectives:
1. To review the different dose reduction techniques used on cardiac CT.
2. To understand the clinical impact, if any, of dose reduction.
3. To recognise when the dose is too low and the noise too high.
A‑054 17:00
C. Cardiac post-processing: latest tricks
B.J. Wintersperger; T oronto, ON/CA (
[email protected])
Proper linking of the data acquisition to the patients ECG is among the crucial
prerequisites for successful cardiac imaging. While cardiac CT data acquisition
itself does not impose any effect on the patients’ ECG, inherent physical effects in
the MR environment does show impact on the ECG trace and may hamper proper
R-peak delineation. In addition, patient-related factors such as arrhythmia might
affect image quality (IQ). Dose saving strategies in cardiac CT limit the possibilities
of retrospective IQ optimisation and as such more emphasis is recommended prior
to data acquisition which is mainly related to patient selection/heart rate control. In
cardiac MR a high amplitude ECG without influence of magnetic or scanning effects
is of outmost importance. Arrhythmia also remains a challenge that might be over-
come by arrhythmia-rejection algorithms or real-time imaging. Suboptimal contrast
enhancement ought to be avoided by proper planning and timing as the majority of
post-processing algorithms is based on signal behaviour. In the unfortunate situation
of suboptimal contrast enhancement often only the use of standard post-processing
tools is possible while semi-automated tools for cardiac post-processing may fail or
necessitate substantial user interaction. The use of straight forward visualisation
techniques is recommended for diagnosis while complex visualisation tools may add
on confidentiality but are mainly suited for case presentations. Coronary evaluation
is typically performed using centerline tools allowing for the easy assessment of
CAD. While these tools potentially allow for estimation of the degree of diameter
and area stenosis, accuracy though may still be limited.
Learning Objectives:
1. To learn how to reduce ECG trigger artefacts on CT and MR.
2. To learn how to compensate for suboptimal contrast enhancement.
3. To learn how to choose appropriate visualisation techniques.
16:00 - 17:30 Room L/M
Professional Challenges Session
PC 2
Radiology and nuclear medicine: really a joint
venture
Moderators:
É. Breatnach; Dublin/IE
P. Bourguet; Rennes/FR
A‑055 16:00
Chairmen’s introduction
É. Breatnach1, P. Bourguet2; 1Dublin/IE, 2Rennes/FR (
[email protected])
This is the second session between ESR and EANM at each Society’s Annual
Congress. Few would argue but that patient’s interests are best served by cross-
fertilisation and open communication between specialties. This is particularly true
for radiology and nuclear medicine. This session elaborates on clinical scenarios
where cross-fertilisation between both specialties is particularly important. The
session will elaborate the radiologist and nuclear medicine perspectives on two
common clinical scenarios, i.e. tumour response to therapy and evaluation of
Alzheimers disease.
Session Objectives:
1. To appreciate how nuclear medicine and radiology provide complementary
information.
2. To learn how each method can enhance the mutual performance of the
radiologist and nuclear medicine physician.
3. To learn about recent advances in the field of tumour evaluation and early
detection of Alzheimer’s disease.
Postgraduate.Educational.Programme
S20
A B C D E F G H
shown on MDCT-images in the axial, coronal, and sagittal plane. Variants of the nor-
mal anatomy, which are important to describe and to know are also shown. Some of
these variants are also delineated on MR images. In the second part of the lecture, the
different expressions of congenital malformations of the external and middle ear will
be explained. The different findings of the severity of the malformations will be shown
and their importance for further clinical-therapeutical procedures will be explained.
Learning Objectives:
1. To review the normal anatomy of the external auditory canal and middle ear.
2. To become familiar with the most frequent malformations of the middle ear.
3. To learn about imaging protocols.
A‑061 16:30
B. Cholesteatoma and chronic infection
F. Veillon; Strasbourg/FR (Francis.Veillon@chru‑strasbourg.fr)
Imaging investigation of cholesteatoma is required before surgery. If no surgery has
been performed previously, CT will provide information about the location of the
lesion (epi, pro, meso, retro, hypotympanum), the partial or total destruction of the
ossicles, and possible extension to the inner ear. If there is no doubt about any of
these factors CT is sufficient. In doubtful cases an MRI examination is performed
to confirm or refute the presence of cholesteatoma using T1 sequences without IV
contrast medium, and diffusion weighted imaging with or without high resolution
T2, depending on the age of the patient. In postoperative recurrent cholesteatoma,
MRI is becoming the modality of first choice for detecting cholesteatomas, appear-
ing : low in signal on T1 sequences, high in signal on diffusion weighted imaging.
However, care is required since performing diffusion weighted imaging without T1
may lead to false positives. A granuloma with a slightly or markedly increased T1
signal is often associated with a high signal on diffusion. Measurement of ADC is
useful for detecting cholesteatomas, infected cholesteatomas or abscess. Finally
whilst MRI is the first examination in the follow -up of postoperative patients, the
use of contrast medium is not necessary in most of the cases.
Learning Objectives:
1. To learn about different causes of hearing loss within the external auditory
canal and middle ear.
2. To learn about a template for a structured report.
A‑062 17:00
C. Implants and postoperative findings in the middle ear
B. Verbist; Leiden and Nijmegen/NL
Many conditions which affect the function of the middle ear may require surgical
intervention. Postoperative imaging will be requested either to evaluate complete
removal of diseases (eg in cholesteatoma) or because of new, persisting or recurrent
complaints of the patient (e.g. vertigo after stapes replacement). In this presenta-
tion, different surgical procedures will be reviewed including the indications for a
certain surgical approach as well as the different types of prosthesis. The normal
postoperative imaging appearance of the most common surgical techniques will be
shown. It will be discussed whether CT or MRI should be performed to answer the
clinical questions. An overview of possible failures and complications will be given.
Learning Objectives:
1. To become familiar with typical implants.
2. To review expected and unexpected postoperative findings.
3. To learn about a template for a structured report.
16:00 - 17:30 Room P
Vascular
RC 215
Extracranial vascular malformations: imaging
strategies prior to endovascular therapy
Moderator:
J.E. Jackson; London/UK
A‑063 16:00
Chairman’s introduction
J.E. Jackson; London/UK (
[email protected])
The management of patients with vascular malformations is often suboptimal. The
reasons for this are many but include confusion regarding classification, uncertainty
about the most appropriate imaging of the various forms of malformation and a
sures are helping to propose new diagnostic criteria for AD, allowing a diagnosis
of probable AD in predementia stages, when memory loss criteria are attached
to Imaging criteria (MRI or PET) or measures of amyloid/tau in CSF. The use of
atrophy markers (global or MTL) increases the effectiveness in clinical trials (both by
reducing the size of the sample and increasing the statistical power) and is therefore
contributing significantly to the development of new treatments. The association of
multiple markers of structural and functional imaging (MRI and PET) and the use
of advanced computational analysis techniques will allow better management of
AD but it needs a broader validation and know the most efficient combination of
biomarkers at each stage of the disease, including the preclinical period.
Learning Objectives:
1. To become familiar with the early signs that enable the detection of
Alzheimer’s disease.
2. To understand the specific role of MRI and to learn the appropriate protocols.
3. To learn about the new developments in radiological detection of Alzheimer’s
disease.
A‑059 16:59
Alzheimer’s disease: the role of nuclear medicine
K. Tatsch; Karlsruhe/DE (Klaus.T atsch@klinikum‑karlsruhe.de)
Scientists, researchers and clinicians all benefit from molecular imaging in dementia
providing exciting new insights into their basic biology and pathophysiology. Tar-
geting specific aspects of neurotransmission, metabolism, inflammation or plaque
formation - just to mention some of the current molecular approaches - increasingly
gains impact on establishing the correct diagnosis, following the course of dementia
or developing CNS drugs. This talk will highlight the molecular targets and major
PET and SPECT tracers for application in dementia, and will update on the results
of the clinical imaging studies published in recent years. Typical imaging patterns of
Alzheimer‘s disease (AD) will be discussed, including also the diagnostic discrimi-
nation from other types of neurodegenerative dementias such as frontotemporal
dementias, Lewy body dementia, and others. Assessment of MCI patients and the
probability of transition in manifest dementia (predominantly AD) will be addressed
together with its prognostic relevance. Furthermore, recent advances in analysing
tools which further improved the high diagnostic accuracy already reached by visual
assessments will be presented. Even though in competition with other modalities,
‚standard FDG‘ PET has shown to be a robust and both, sensitive and specific
marker in the diagnostic work-up of dementia. FDG information will be markedly
extended in clinical practice by specific amyloid imaging in the near future when
these tracers are approved and thus generally available.
Learning Objectives:
1. To become familiar with the nuclear medicine method that enables detection
and evaluation of Alzheimer’s disease.
2. To learn about the potential development of functional studies using nuclear
medicine.
3. To understand how nuclear medicine and radiology can provide
complementary information.
Panel discussion:
The advantages of working together for nuclear
medicine and radiology 17:17
16:00 - 17:30 Room N/O
Head and Neck
RC 208
An insight into middle ear pathologies
Moderator:
T.J. Vogl; Frankfurt a. Main/DE
A‑060 16:00
A. Normal anatomy and congenital malformations of the middle ear
C. Czerny; Vienna/AT (
[email protected])
Imaging of the middle ear is either performed by CT and/or MRI. As the normal middle
and external ear consists mostly of bony structures and air, CT in the bone-window-level
setting is the method of choice to delineate the normal anatomic structures. Especially,
high-resolution MDCT in bone-window-level setting excellently depicts even subtle
normal as well as abnormal osseous structures. However, pathologic conditions are
also well delineated such as those of inflammation or cholesteatoma. In this lecture,
the normal anatomic structures of the external and middle ear will be explained and
Thursday
Postgraduate.Educational.Programme
A
S21
CB D E F G H
symptoms may require explanation and reassurance only. Lesions with a mainly
cutaneous element may be treated with laser. Deeper lesions are usually treated
with several episodes of sclerotherapy. Agents such as alcohol, polidocanol and
STD will be discussed and the relative advantages and issues explained. Informed
consent is vital, and the approach to this will be outlined. High flow lesions are fre-
quently associated with severe cosmetic changes, invasion of surrounding tissues,
haemorrhage, and high output cardiac failure. Lesions may be life threatening. In
the extremities peripheral ischaemia and ulceration due to steal of blood by the
arteriovenous malformation is common. Informed consent will again be discussed,
as potential for major complications is high. Key to endovascular management of
these lesions is an understanding of the nidus, arterial inflow and venous outflow.
The role of liquid and solid embolic agents and specifics of transarterial, venous
and direct approaches will be discussed.
Learning Objectives:
1. To learn the principles of endovascular treatment including sclerosing and
embolisation materials and catheterisation techniques.
2. To discuss the hazards and complications of treatment.
3. To discuss the endpoints of treatment.
Panel discussion:
Who should decide management? 17:14
AVMs pose a major problem regarding classification and treatment. A case report
discussed by the panellists demonstrates how these patients should be ap -
proached. The importance of establishing an interdisciplinary outpatient clinic is
also presented. The most important organisational steps for providing an efficient
clinical service are given. In addition, the most common pitfalls and complications
of treatment are illustrated.
16:00 - 17:30 Room Q
Computer Applications
RC 205
Computer-aided detection/diagnosis
Moderator:
E. Pietka; Gliwice/PL
A‑067 16:00
Chairman’s introduction
E. Pietka; Gliwice/PL (
[email protected])
Computer-aided detection/diagnosis (CAD) is recognised as a workstation or a
system developed in order to assist the radiologists (clinicians) in performing their
daily diagnostic tasks. Clinically implemented CADs are available at workstations
and (if DICOM compliant) may serve as a plug-in to PACS. The three-layer CAD
system includes: (1) image analysis procedures whose development requires
a medical and technical knowledge, (2) a database module that is managed by
experienced radiologists and IT professionals, and (3) graphical user interface
(GUI) that enables a user-friendly access to the data, the processing tools, and
the results. A modern CAD development involves a multidisciplinary team whose
members are experts in medical and technical fields. A close collaboration of all
experts is required at all stages of system life-cycle. At each stage the physicians
knowledge and experience are indispensable. It includes medical analysis of the
diagnostic problem, data collection, image analysis evaluation, and clinical verifica-
tion. Design, testing, and evaluation have to be successful in order to ensure CAD
implementation in a daily clinical routine. In this session three experts will share their
experiences in the area of the overall CAD architecture, its evaluation, validation
and acceptance by clinicians, advantages and restrictions of solutions and clini -
cal implementation in lung, breast and colon cancer. Reading paradigm (primary,
concurrent, second) in oncology as well as results of CAD clinical implementation
will be presented. Perspectives in clinical CAD implementation in diagnosis and
treatment will be discussed.
Session Objectives:
1. To understand what the radiologist should know about CAD.
2. To understand the role of the radiologists in CAD development.
3. To learn about the main challenges for CAD implementation.
4. To understand the impact on radiological practice.
poor understanding of the indications for intervention. This session will concen -
trate upon these important topics and will also address some technical aspects
of endovascular therapy.
A‑064 16:05
A. Pathology, correct anatomical classification and clinical work-up
H. Kubiena; Vienna/AT (
[email protected])
Patients presenting with vascular malformations mostly are nomadic and hopeless
individuals looking for help. Finally having reached a “multidisciplinary specialist-
group” after a sometimes long and misleading trip throughout the ocean of “single-
players” of different specialities these patients do not ask for any more diagnostics
- they strongly claim for therapy. Vascular malformations are congenital lesions,
although merely seen at birth they become evident throughout the individuals
growth. These developmental errors can affect all components of the vascular tree
in any area of the body. The therapeutic goal must be defined rather as “control”
than “cure” of this disease. To make this point understandable for both patients and
collegues a fundamental understanding of the pathogenesis and natural course
must be created. In special cases of complex vascular malformations the precise
diagnosis and the information about all potential side-effects as well as risk-factors
of progression enables these patients to manage their daily life. Therefore, indica-
tions for treatment vary depending on the specific type of slow flow or high flow
lesion, location, pain, functional and cosmetic impairments and general side-effects
of each particular lesion, since no single specialist has enough knowledge to
diagnose or treat vascular anomalies beyond the border of his distinct speciality
multidisciplinary working-groups emerged at these interdisciplinary interfaces. Their
common language in classifying and their overall understanding of pathogenesis,
prognosis offer these mostly hopeless patients a custom-fit treatment addressing
their symptoms.
Learning Objectives:
1. To understand the pathology of capillary, venous, lymphovenous and
arteriovenous malformations.
2. To understand the haemodynamics of vascular malformations.
3. To discuss the clinical symptoms and the indications for treatment.
A‑065 16:28
B. Imaging of capillary, venous, lymphovenous and arteriovenous
malformations
L. Schultze Kool; Nijmegen/NL (
[email protected])
Imaging of vascular malformations should be directed by clinical assessment of the
type of malformation to be expected, clinical symptoms and need for treatment. In
order to make the proper decision of the required imaging modality or treatment, it
is essential that the (interventional) radiologist is a member of a dedicated vascular
malformation team. Imaging needs to be tailored to the individual patient although
general rules can be applied. Duplex ultrasound together with a clinical assess-
ment is often sufficient to make a proper diagnosis. This is especially true for the
paediatric population. If more information about the extent of the lesion is needed,
MR is often used in case of low flow lesions (venous/lymphatic), and MRA or CTA
in case of high flow lesions. Angiography is mandatory if an AVM is diagnosed
and treatment is planned. High frame rate imaging and selective injections are the
only options for a proper evaluation of the nidus architecture of the AVM. There
are exceptions that warrant deviating from the above general rules. In this lecture,
both the general rules and the exceptions will be discussed.
Learning Objectives:
1. To consolidate knowledge of the various imaging techniques including their
potential for visualising the anatomy and haemodynamics.
2. To learn criteria for classification of vascular malformations.
3. To learn reporting standards for vascular malformations.
A‑066 16:51
C. Technical aspects of endovascular treatment
P.C. Rowlands; Liverpool/UK (
[email protected])
Vascular malformations are uncommon conditions with a wide spectrum of ap-
pearance and symptoms. Incorrect diagnosis and management is common. Best
outcomes are obtained in centres with a high caseload and multidisciplinary
management. The disciplines include interventional radiology, plastic surgery,
dermatology, anaesthesiology, vascular surgery and others. Accurate diagnosis
by clinical assessment and non-invasive imaging is key to procedural planning.
Low flow and high flow lesions are managed very differently and are discussed
separately below. Low flow lesions may be associated with symptoms varying
from trivial to significantly affecting quality of life. Patients with lesions with mild
Postgraduate.Educational.Programme
S22
A B C D E F G H
A‑070 16:51
C. CAD in oncology: from principles to clinical implementation
E. Neri; Pisa/IT (
[email protected])
CAD has been developed to help radiologists in detecting pathology. In the era
of screening radiologists are asked to read a large amount of x-ray, CT and MRI
examinations; readers fatigue increases the risk of interpretation errors; therefore,
systems that help radiologists in detecting pathology are welcome. CAD is the
natural solution; however, is it ready to be used in the clinical and especially in
the screening setting? How it works? CAD uses algorithms that identify specific
shapes and densities into a DICOM image. The CAD compares this features with
an internal database and through a learning curve reach a decision and marks
the pathological findings. Which are the oncological applications of CAD. Three
fields actually seems to be well established and promising: detection of polyps in
CT colonography, breast lesions in x-ray mammography, and nodules in CT of the
lungs. These 3 oncological applications of CAD will be discussed in the presentation.
Learning Objectives:
1. To review the principles of current CAD systems in the detection of lung,
breast and colon cancer.
2. To understand the reading paradigm (primary, concurrent, second) in
oncologic applications of CAD.
3. To understand the results of CAD clinical implementation.
4. To learn about future perspectives of CAD in oncology (which other
applications?).
Panel discussion:
The take-home points 17:14
1. Modern CAD system architecture
2. Open source solutions: advantages and restrictions
3. CAD clinical implementation
4. Future perspectives of CAD
18:30 - 18:50 Room A
Plenary Session
OL
Opening Lecture
Presiding:
Y. Menu; Paris/FR
A‑071 18:30
Water: radiologists' best friend?
D. Le Bihan; Gif‑sur‑Yvette/FR (
[email protected])
At the onset of the 21 st century humankind is focusing its attention on a very
small molecule, as controlling CO 2 in the atmosphere is becoming a major goal,
economically, socially and politically. Yet, there is another small molecule which is
going to play a more prominent role in the near future. H2O, especially in its liquid
form, the ‘Blue Gold’, is just indispensable to our lives. Water makes 60 to 70% of
the human body weight and is crucial to the working of the biological machinery.
Still, how such a tiny molecule with its 105° ‘magic’ angle could have been at the
origin of life remains largely a mystery. Different organisms have adopted different
strategies in the way they get the most out of water, depending on their environ -
ment, and water contributes to the biodiversity. Faulty mechanisms in the use of
water by tissues may lead to severe diseases or death. Clearly, water deserves to
be seen as the prime ‘biological molecule’, and radiologists have long recognised
its importance from the days of ‘dry’ (bone and air) radiology to the advent of CT
which allowed contrast from ‘wet’ tissues to be explored. With MRI one went one
step further, as magnetisation of water is the sole source of contrast. Life has led
to intelligence, and recent MRI studies have suggested that water may also actively
contribute to the mechanisms underlying brain function. Could the ‘molecule of life’
also be the ‘molecule of the mind’? Clearly, water must be radiologists' best friend.
Learning Objectives:
1. To comprehend how the structure of the water molecule makes it important
to life.
2. To understand the importance of water in biological and cellular processes.
3. To become familiar with the different ways water is responsible for image
contrast in radiology.
A‑068 16:05
A. The role of CAD in modern-day imaging
A. Todd-Pokropek; London/UK (A.T
[email protected])
The use of CAD in medicine is an important and growing area of research. Firstly
good data must be acquired including not just images but associated information.
The first step in that of preprocessing, notably (but not only) noise reduction. The
data are then passed onto the segmentation step. Often this step is semi-automatic
requiring some manual intervention. Conventional edge detection methods are not
often of value, but Active Shape and Appearance Models, the use of Markov Ran-
dom Fields etc are commonly used. The next step is that of feature extraction both
of shape and texture. These data are then submitted to one of several classifiers
such as Artificial Neural Networks (including MTANNs) Support Vector Machines
(SVM) and data reduction using Principle and Independent Component Analysis,
and Multiple voting techniques such as ADABoost are also of value. The output
may simply be returned to the observer (clinician) or as further input for a decision
support system. Examples considered will be in breast imaging (mammography),
lung nodule detection, virtual colonoscopy and lumber spine. The use of the CAD
system as a simultaneous assistant or as a second reader is important. The use
of CAD in therapy is of increasing important. The assessment of such CAD system
(evaluation and validation) is still controversial. The difficulty of bringing systems
both instrumentation and software for use in clinical practice in often underestimated
and there have been some notable failures. Some example of ‘failures’ will be given.
Learning Objectives:
1. To review several current CAD systems and architecture from a general
point of view.
2. To understand the problems of evaluation, validation and acceptance by
clinicians.
3. To learn about potential future applications such as assessment of therapy.
4. To become familiar with the potential implications of advances such as the
Grid.
A‑069 16:28
B. Emergence of open-source software
O. Ratib; Geneva/CH
In the recent years, open source software (OSS) has grown in numerous areas
of software development including in highly specialised markets such as medical
applications. This new paradigm in software development has proven to be cost
effective and successful in many areas including medical imaging applications. It is
particularly promising in advanced image display and analysis applications where
the rapid increase in demand cannot be matched by traditional expensive com-
mercial solutions. The evolution of radiology imaging modalities from 2D sectional
acquisition to 3D volumetric acquisition and even higher dimensions with functional
data and the emergence of multimodality scanners such as PET/CT scanners calls
for new and innovative display and visualisation tools. By combining multiple new
technologies and open-source projects it is possible to develop a new generation
of high-performance 3D DICOM viewers that were traditionally only accessible
on expensive 3D workstations restricting their use to specialist radiologists. An
example of such open source project is the OSIRIX software for multimodality
image analysis and processing. It provides the necessary tools for navigating and
processing very large datasets of multimodality imaging. It can be implemented
outside radiology departments and provide a solution for increasing needs and
requirements of clinicians, surgeons and other specialists. Open source software
platform can provide cost-effective framework for the development and wide dis-
tribution of advanced image processing and image analysis tools. It can ensure
sustainability and large diffusion of specialised analysis tools that would otherwise
be very difficult to distribute and maintain outside its original development lab.
Learning Objectives:
1. To learn about the advantages and restrictions of open-source solutions.
2. To understand how open-source solutions could be implemented.
3. To learn about specific open-source tools.
4. To understand the legal aspects of clinical applications of open-source
software.
Postgraduate.Educational.Programme
A
S23
CB D E F G H
Friday,.March.4
Postgraduate.Educational.Programme
S24
A B C D E F G H
(CRC) screening. The reason was that the data from the major multicenter trials
showing benefits in CRC screening by the use of CTC are not applicable to the
average Medicare population because of the differences in age; and the older the
age the larger the number of polyps with a consequent increase in colonoscopy
referral, leading to exam duplication. This is the same policy of almost all the pri-
vate contractors in the US as well as the European countries, where both private
and public payers are not covering CTC for CRC screening. Reason is that even
optical colonoscopy is not considered a screening test in Europe, where authori -
ties recommend the use of faecal occult blood test (FOBT). In some European
countries, for example in Italy, CTC is integrated into mass screening projects
performed with FOBT as a substitute of barium oenema in the case of incomplete
optical colonoscopy performed in individuals with a positive FOBT. The situation
is different for other clinical conditions and, in particular, for those patients with a
previous incomplete optical colonoscopy, due to obstructing neoplasm, aberrant
anatomy, previous surgery, etc., where CTC is fully reimbursed. And the same
occurs in most countries when there is an absolute contraindication to invasive
colonoscopy or preoperative cancer staging and localisation is needed.
Learning Objectives:
1. To become familiar with differences in reimbursement for CTC within
and outside Europe, and to detail how this differs for symptomatic and
asymptomatic patients.
2. To understand how differences in reimbursement impact on implementation
of CTC.
3. To understand broader political issues related to reimbursement, namely
turf-battles with other health professionals.
4. To become familiar with potentially imminent changes in reimbursement.
A‑075 09:09
Quality, training and accreditation
D. Burling; London/UK (
[email protected])
CT colonography has evolved rapidly and disseminated widely over the last decade.
The ability to provide an accurate whole colon examination with near perfect comple-
tion rates, use of reduced laxative bowel preparations and extra-colonic organ review
has attracted very considerable interest amongst the wider radiological and gastro-
enterological community. Inclusion of CT colonography in several core radiological
training programmes confirms its evolution from super-specialist technique (performed
in only a few centres) to mainstream. However, evidence supports highly variable
performance, which is perhaps unsurprising given the complexity of both technique
and interpretation methods - both which require specific training. Notably, attendance
at a training workshop generally represents the beginning of a radiologist’s experi-
ence of CT colonography. Indeed, most delegates rapidly progress from unconscious
to conscious incompetence, acknowledging the need for a planned implementation
strategy prior to offering CT colonography in their routine clinical practice. Thankfully
a decade of intensive research and large volume clinical experience has equipped
the radiological community with knowledge and experience to inform successful CT
colonography implementation strategies. By combining this experience with training
and accreditation practices developed for colonoscopy, the prospect of a robust quality
assurance framework is realistic and necessary to reassure both service commissioners
and the general public alike. Step one: the publication of international CT colonography
standards, co-authored by eminent radiologists from across Europe and beyond has
been achieved. This talk will review the likely next steps.
Learning Objectives:
1. To learn about trial data that quantify the benefit of training individuals to
interpret CTC.
2. To become familiar with a quality framework necessary for optimised CTC
data acquisition, interpretation, and patient satisfaction, with reference to the
BSGAR/RCR/ESGAR guidelines.
3. To learn how the above may be implemented practically.
4. To learn about issues around potential accreditation for CTC, both practical
and political.
A‑076 09:27
CAD: friend or foe?
S. Halligan; London/UK (
[email protected])
Computer-assisted detection (CAD) for CT colonography is now widely available
in Europe from a number of different vendors. This presentation will detail factors
that potential users will need to know in order to properly evaluate CAD systems,
use them in clinical practice, and evaluate their likely impact. The different ways in
which the performance of CAD systems can be assessed will be discussed and the
difference between weak methodologies (e.g. internal validation) and more valid
assessments (e.g. external validation) will be explained. The different possibilities
08:30 - 10:00 Room A
State of the Art Symposium
SA 3
The 3 P’s of CT colonography: polyps, protocols
and politics
Moderator:
S. Halligan; London/UK
A‑072 08:30
Chairman’s introduction
S. Halligan; London/UK (
[email protected])
Now that the diagnostic performance of CT colonography has been well-established,
this state-of-the-art symposium will deal with issues related to the implementation CT
colonography in day to day clinical practice. The lecturers will deal with the diagnostic
performance of CT colonography, the technical requirements necessary to obtain high
quality diagnostic data, the factors that underpin a high-quality service (including reader
training), how implementation differs across different countries, and the possible impact
of new developments, including computer-assisted detection (CAD).
Session Objectives:
1. To review current technical prerequisites for acquisition of high-quality CTC
data and its visualisation.
2. To learn about political and turf-battle issues surrounding implementation of
CTC technology.
3. To recognise the characteristics of a high-quality service, both for patients
and doctors.
4. To understand the benefit of CAD assistance for data interpretation.
A‑073 08:33
CT colonography in 2011: how far has it come
P. Lefere; Roeselare/BE (
[email protected])
Two decades ago spiral CT technology initiated a new era in diagnostic imag-
ing with virtual colonoscopy or CT colonography (CTC) as a major innovation.
Introduced by David Vining in 1994, CTC was rapidly endorsed as a potential
tool for colorectal cancer screening. After an initial pioneering period defining the
basic CTC principles, the advent of multi-slice CT significantly improved spatial
and temporal resolution, allowing for isotropic image reconstruction with detailed
3D rendering of the colonic wall and very short acquisition times, reducing motion
artefacts. Furthermore, application and refinement of (ultra-) low dose technique
almost completely tackled the issue of radiation dose. These improvements have
resulted in the perfect optical colonoscopy imitator with reliable fly through of the
colon in a timely manner. Consecutively, the primary 3D reading paradigm with 2D
problem-solving is getting more and more adepts, although in experienced hands
primary 2D-read with 3D-problem solving is a solid contender. To improve depiction
of the colonic wall new 3D visualisation methods were developed. These technical
improvements with the application of state-of-the-art CTC technique have resulted
in a very good performance of polyp detection. In three multi-centre studies, totalis-
ing 3775 patients, sensitivity ranged between 78-91% and 90-92% and specificity
between 84-93% and 84-98% for lesions > 6 mm and > 10 mm, respectively.
Finally, it may be expected that further refinements of CAD, laxative-free CTC with
electronic cleansing and dual energy CT will bring CTC to the next level and will
enhance it as the reliable and cost-effective tool for colorectal cancer screening.
Learning Objectives:
1. To review the evolution of CT colonography since its introduction, with
a focus on data acquisition and methods of data visualisation and
interpretation.
2. To review the currently achievable test characteristics of CTC (sensitivity,
specificity, accuracy) via reference to current trial data.
3. To become familiar with imminent developments that may further enhance
CTC test characteristics.
A‑074 08:51
Current status of reimbursement
A. Laghi; Latina/IT (
[email protected])
Current status of reimbursement for CT colonography (CTC) is extremely het-
erogeneous, both within and outside Europe. In the US, in 2009, the Centers for
Medicare and Medicaid Services denied coverage for CTC for colorectal cancer
Friday
Postgraduate.Educational.Programme
A
S25
CB D E F G H
astinitis and extension of infection from adjacent spaces (neck, pharynx, pleura or
retroperitoneum). Typical cases including the role of radiologic findings with respect
to sensitivity and specificity, and important differential diagnosis will be discussed.
The distinction between a parapneumonic pleural effusion and an empyema based
on radiologic findings is often impossible. Features suggesting a “complicated”
course requiring interventional or even surgical treatment at some point will be
discussed. Features of empyema and lung abscess at CT will be illustrated as well
as CT indices of severity of empyema and its effect on the underlying lung that allow
some prediction of functional outcome after surgical decortication. An empyema
necessitatis describes a chronic empyema that attempts to decompress through
the chest wall. Infectious agents include tuberculosis, actinomyces, staphylococcus
and various types of fungi. It has to be differentiated from other mostly neoplastic
diseases that cross fascial planes such as lymphoma or Pancoast tumour.
Learning Objectives:
1. To review the most common conditions or infectious agents that cause non-
pulmonary thoracic infections.
2. To learn about the role of various imaging techniques including ultrasound,
CT and MRI for the assessment of chest wall, pleural or mediastinal
infections.
3. To be aware of the differential diagnosis and to know about imaging features
that are helpful in this matter.
08:30 - 10:00 Room C
Abdominal and Gastrointestinal
RC 301
Abdominal lymphoma
Moderator:
A. Rahmouni; Creteil/FR
A‑079 08:30
A. Solid organs
E. de Kerviler; Paris/FR (eric.de‑
[email protected])
Most lymphomas arise in lymph nodes or other lymphatic tissues. Extranodal
lymphomas arise in tissues normally devoid of lymphoid tissue. Involvement of
so-called extranodal organs is a common finding after staging investigation, how-
ever, and a substantial part of NHL even arises in these sites. The latter form is
often referred to as primary extranodal NHL. Splenic lymphoma is common in both
Hodgkin disease and non-Hodgkin lymphomas but it may be difficult to detect by
imaging techniques because lymphoma nodules in the spleen are often smaller
than 1 cm. Splenic enlargement alone is not a good indicator of lymphomatous
involvement. Primary hepatic lymphoma is rare compared with disseminated
diseases at both nodal and extranodal sites. Several forms of hepatic involve -
ment can be seen including mass lesions/nodules, diffuse infiltrative form and
extrahepatic involvement of the hepatic ligament. Lymphomatous involvement of
liver hilum nodes often infiltrates along the hepatic artery and portal vein toward
the head of the pancreas and produces an infiltrative bulky mass that involves the
liver, pancreas and duodenum. Primary pancreatic lymphoma is very rare and can
be difficult to differentiate from pancreatic adenocarcinoma. Definitive pathological
diagnosis of lymphomas is often obtained using image-guided biopsy. This non-
invasive procedure is important as the prognosis and management of lymphomas
differ greatly from that of adenocarcinoma or metastatic diseases. Staging (Ann
Arbor classification or modifications) and response to therapy is primarily by CT.
Indications for 18 F-PET/CT include lymphomas that are routinely FDG avid, diffuse
large B-cell lymphomas and Hodgkin disease.
Learning Objectives:
1. To review the pathways of spread in liver and spleen lymphoma.
2. To learn the various imaging features of liver and spleen lymphoma and their
differential diagnoses.
3. To learn to identify the accuracy of each imaging modality to assess staging
and response to therapy.
A‑080 09:00
B. Hollow abdominal viscera
R.M. Mendelson; Perth/AU (
[email protected])
Primary gastrointestinal lymphomas are nearly always NHLs, classified pathologi-
cally by the REAL/WHO system. Correlation of radiological morphology with histol-
ogy is relatively poor, but characteristic subtypes are discussed. The key issue is
differentiating indolent and aggressive lymphomas. Most gastric lymphomas are
for integrating the CAD system into day to day clinical workflow will be explained,
particularly second-read CAD and concurrent CAD. Finally, the clinical impact of
CAD and the different reading paradigms will be quantified with reference to the
peer-reviewed indexed literature.
Learning Objectives:
1. To understand what CAD is and how it is integrated into clinical interpretation
of CTC.
2. To review trial data that quantifies the benefit of CAD assistance to
observers tasked with interpreting CTC.
3. To learn which observer groups may benefit most from CAD, and its impact
on training schedules.
Panel discussion:
In 2011, should CTC now be the primary method of colorectal investigation
in my hospital? 09:45
CTC is now established in clinical practice but other viable methods for colonic
investigation remain; namely barium enema and colonoscopy. CTC has attracted
most attention as a screening method for colorectal cancer and adenomas, but
a role is also advocated for symptomatic patients, not only because it can detect
symptomatic cancer but because disease outside the colon may underpin symp-
toms. The panel will debate whether the barium enema should be abandoned
completely and, if so, will discuss the relative positioning of CTC and colonoscopy
for investigation of symptomatic patients.
08:30 - 10:00 Room B
Interactive Teaching Session
E³ 320a
Thoracic infections: what the radiologist must
report
A‑077 08:30
A. Pulmonary infections
T. Franquet; Barcelona/ES (
[email protected])
Community acquired pneumonia (CAP) is a major health care problem because
of their high morbidity and mortality rates. Patients exposed to non-hospital risks
who develop pneumonia have been traditionally categorised as having community-
acquired pneumonia (CAP). Healthcare-associated pneumonia (HCAP) is a new
designation for pneumonias affecting individuals residing in non-hospital health
care facilities, patients undergoing outpatient procedures or therapies, and patients
who have been recently discharged from the hospital setting. When the diagnosis
of CAP or HCAP is suspected, imaging studies are mandatory for the evaluation
of affected patients. A nosocomial pneumonia is defined as one not acquired in a
hospital or a long-term care facility. It occurs most commonly among ICU patients,
predominately in individuals requiring mechanical ventilation. Pulmonary infection
is a major cause of morbidity and mortality in patients with impaired immune func-
tion. Increasing numbers of patients are becoming immunosuppressed, because
of solid organ and hematopoietic stem cell transplantation, the use of immunosup-
pressive agents for treating a host of inflammatory diseases, or congenital and
acquired diseases such as acquired immune deficiency syndrome (AIDS). Mildy
impaired host immunity as it occurs in chronic debilitating illness, diabetes mellitus,
malnutrition, alcoholism, advanced age, prolonged corticosteroid administration
and chronic obstructive lung disease have also been regarded as predisposing
factors of pulmonary infections. The rapid diagnosis and treatment of pulmonary
infections are essential. Combination of pattern recognition with knowledge of the
clinical setting is the best approach to pulmonary infectious processes.
Learning Objectives:
1. To learn how to recognise pulmonary infections in immunocompetent and
immunodepressed patients.
2. To learn how to recognise infections of the chest wall, pleura and
mediastinum.
A‑078 09:15
B. Non-pulmonary chest infections
C. Schaefer-Prokop; Amersfoort/NL (
[email protected])
Acute mediastinitis is a potentially life threatening but fortunately rare condition that
requires prompt diagnosis and treatment. Spontaneous or iatrogenic oesophageal
rupture is the by far most common cause. Other causes include post-surgical medi-
Postgraduate.Educational.Programme
S26
A B C D E F G H
ask the patient for those information. At the time of MR imaging plain films and/
or results of an ultrasound exam of the shoulder, if possible, should be available.
However, only such prerequisites allow to run a tailored examination protocol and
to support the orthopaedic colleague with the needed answers for further adequate
therapy. The patient has to be placed in the magnet in a pleasant situation to avoid
artefacts due to patients movement, which usually cause motion artefacts. It is very
important to explain to patients to keep quiet during the whole examination, because
artefacts may need repetitions of sequences, and lead so to prolongation of total
examination time. Furthermore, they make diagnosis more difficult and eventually
more or less inaccurate. Lastly, sequence repetitions decrease patient throughput
and therefore cost effectiveness. Imaging in three orientations (axial, paracoronal-
parallel to the supraspinatus tendon, and parasagittal - parallel to the glenoid cavity)
using T1W (PDW) and/or T2W sequences have to be performed. In case of specific
questions regarding lesions of the labrum intraarticular administration of contrast
agent (MR arthrography) should be considered, which is sometimes (different from
country to country) possible after discussion with referring orthopaedic surgeon only.
Learning Objectives:
1. To understand the influences of patient positioning, scan parameters and
magnet/coil technology on image quality.
2. To learn how to optimise scan protocols to maximise patient throughput
without compromising diagnostic quality.
3. To recognise how and when to modify scan protocols to answer specific
clinical questions.
A‑083 08:55
B. Normal variants and pitfalls
M. Reijnierse; Leiden/NL (
[email protected])
MR arthrography is superior to other imaging techniques in the evaluation of the
glenohumeral joint. Knowledge of normal anatomy on MR arthrography is essential
to identify pathology. Three glenohumeral ligaments (GHL) have been described, the
superior GHL, the middle GHL and the inferior GHL complex, formed by an anterior
band, a posterior band and an axillary recess of the joint. The number of ligaments
is variable in any person and their size varies considerably. The SGHL is present in
90-97% of shoulder studies and is variable origin. The MGHL is present in 73-92%.
The IGHL is present in almost 100% of shoulder studies. The MGHL is the least
constant in size and it can be absent in up to 27% of individuals. A well-recognised
variant is the Buford complex, which represents a cordlike thickening of the MGHL,
with absence of the anterior superior portion of the labrum. This variant is seen in
up to 6.5% of patients. Other normal variants that can be diagnostic pitfalls include
the anterosuperior sublabral foramen and hyaline cartilage under the labrum.
Learning Objectives:
1. To become familiar with the normal anatomy.
2. To be able to identify normal variants.
3. To appreciate the range of pitfalls that may simulate pathology.
A‑084 09:20
C. Identifying and reporting abnormal findings
S. Waldt; Munich/DE (
[email protected])
MR imaging (MRI) and MR arthrography are the primary diagnostic imaging modali-
ties applied to patients with degenerative, traumatic and sports-related shoulder le-
sions. In this categorical course the characteristic MR imaging and MR arthrographic
features of articular pathologies of the shoulder, in particular, instability-associated
injuries, rotator cuff tears and biceps tendon lesions are discussed. Beside lesion
detection the radiological analysis comprises the understanding of the underlying
pathomechanism and recognition of possible interrelations between different type
of lesions (for example, secondary impingement and associated lesions of the
posterosuperior labrum). The use of classification systems for specific lesions is
introduced in order to improve the radiological report. A reasonable structure for
written reports is discussed comprising a brief and clear description of pathological
findings with subsequent interpretation and categorisation of findings with a view
of therapeutic decision making.
Learning Objectives:
1. To review imaging appearances of instability lesions, rotator cuff tears and
pathology of the biceps tendon.
2. To understand the use of terminology and classification systems to describe
and categorise these common abnormalities.
3. To recognise underlying pathomechanisms and understand therapeutic
consequences.
B-cell, MALT type. Radiological features depend on histological grade. Small intes-
tine lymphoma patterns are categorised as multiple nodules, infiltrative, polypoid,
endo-exoteric and mesenteric-invasive. Rare primary colonic lymphomas may
be focal or diffuse. Gastrointestinal lymphomas are great mimickers with a wide
differential diagnosis including: in the stomach, Menetrier’s disease, hypertrophic
gastritis and carcinoma; in the small intestine, Crohn's disease, mastocytosis and
metastatic disease (nodular form); inflammatory disease and carcinoid (infiltra-
tive form); GISTs and serosal metastases (cavitating form); TB, Crohn's disease,
carcinoid and carcinoma (fistulation). However, ‘aneurysmal dilatation’ strongly
indicates lymphoma. The ‘hamburger’ sign of mesenteric lymph node enlargement
is characteristic. Staging (Ann Arbor classification or modifications) and response
to therapy is primarily by CT. Indications for 18F -PET or PET/CT include lympho-
mas that are routinely FDG avid, diffuse large B-cell and Mantle cell lymphomas.
PET’s role in other NHLs is less clear. PET can show occult advanced disease,
assess therapeutic response, detect relapse, and differentiate fibrosis/necrosis
from tumour. Although there is no convincing evidence that baseline FDG uptake
intensity is an independent prognostic factor, changes in uptake reflect chemo-
therapeutic response; post-therapy residual uptake correlates with poor prognosis.
Post-therapy negative PET has high NPV for residual disease. Interim PET may
be more accurate that end-of-therapy PET for predicting progression-free survival.
Learning Objectives:
1. To know the various imaging features of gastrointestinal tract lymphoma.
2. To recognise the differential diagnostic criteria from other diseases.
3. To learn to identify the accuracy of each imaging modality to assess staging
and response to therapy.
A‑081 09:30
C. Genitourinary tract involvement
J.A. Spencer; Leeds/UK (
[email protected])
Lymphoma can involve any part of the genitourinary (GU) tract. Manifestations
include a focal mass, multifocal masses or a diffuse process. Lymphoma is one
of the great mimics. When should one suspect a diagnosis of lymphoma? 1. With
immunocompromised patients, e.g. after organ transplantation from post-transplant
lymphoproliferative disorder (PTLD) or with HIV infection. 2. In childhood and ado-
lescence when lymphoma is relatively more common and, with multifocal masses in
the same organ, e.g. the testis or kidney. 3. Bland homogeneous masses. 4. Diffuse
processes infilling whole anatomic spaces, e.g. the perinephric space. 5. Disease
crossing several tissue planes. 6. Bulky disease with few symptoms. The primary
modality for investigation will be determined by the symptoms or clinical signs which
prompt medical attention. Obtaining a tissue diagnosis at the earliest possible op-
portunity is key to planning therapy. The radiologist can do this by a variety of routes
using US or CT guidance and should alert the surgeon to the need for deep biopsies
when a submucosal process seems likely. With prior lymphoma the likelihood that
any new GU problem reflects disease recurrence is guided by expected behaviour of
the original disease. Comparison of the new specimen with material from the original
diagnosis is important. Relapse in extranodal sites such as the GU tract may indicate
transformation to a high grade lymphoma. Overall, diffuse large B-cell lymphoma
(DLBCL) is the predominant diagnosis. CT is the mainstay of monitoring treatment
response. CT-PET has a role for assessment of residual masses.
Learning Objectives:
1. To recognise the varied imaging features of genitourinary tract lymphoma.
2. To understand the differential diagnostic criteria from other diseases.
3. To learn to select appropriate imaging modalities in diagnosis, staging and
assessment of response to therapy.
08:30 - 10:00 Room D1
KISS (Keep It Simple and Straightforward): Musculoskeletal MRI
CC 316
The shoulder
Moderator:
A. Oktay; Izmir/TR
A‑082 08:30
A. How I do it
J. Kramer; Linz/AT (
[email protected])
The first step prior to the examination of an optimal evaluation of the shoulder by
MR imaging consists of a sufficient recommendation with some information of the
patients history and clinical complaints. Not rarely the radiologist himself has to
Friday
Postgraduate.Educational.Programme
A
S27
CB D E F G H
A‑087 08:58
State-of-the-art CT/MR/PET in the treated neck
F.A. Pameijer; Utrecht/NL (
[email protected])
Tissue changes in the treated neck by surgery and/or radiotherapy (RT) make the
detection of residual or recurrent tumour more difficult. Clinical evaluation of the
neck is also hampered by these changes. Therefore, any (non-invasive) method
helping in the detection of recurrence is welcome. In order to evaluate the treated
neck, radiologists should be familiar with expected post-RT findings. Histological
changes post-RT will be discussed in combination with imaging examples. This
knowledge will enable radiologists to recognise non-expected findings post-RT.
Non-expected post-RT findings can be caused either by tumour recurrence, or
by complications of treatment (e.g. chondro-radionecrosis). Imaging examples
will be shown. Especially after surgery, including various types of neck dissection,
lymphatic drainage patterns of the head and neck are altered. It is important that
radiologists are aware of these changes. Imaging examples will be shown. CT
and/or MR-findings in the treated neck may be inconclusive. In these cases, there
may be an additional role for metabolic (PET) imaging. At present, the position of
metabolic imaging in the imaging protocol for the treated neck is unclear. Information
from the recent literature will be discussed. Also, examples from daily practice will
be shown, with emphasis on the importance of base-line imaging after treatment
and the timing of such base-line scans. This knowledge will help in understanding
the current indications and limitations of post-treatment metabolic (PET) imaging
of the head and neck.
Learning Objectives:
1. To become familiar with expected post-radiation CT/MR findings.
2. To become familiar with patterns of lymphatic spread after surgery.
3. To understand the indications and limitations of post-treatment metabolic
(PET) imaging of the head and neck.
A‑088 09:21
New techniques and protocols: perfusion, diffusion, spectroscopy and
new PET tracers
V. Vandecaveye; Leuven/BE (
[email protected])
Computed tomography (CT), magnetic resonance imaging (MRI), and [ 18F]fluo-
rodeoxyglucose positron emission tomography (FDG-PET) are the main imaging
modalities in head and neck cancer. However, the dependency on morphological
and size-related criteria of anatomical imaging and the limited spatial resolution and
FDG-avidity of inflammation of metabolic imaging may reduce diagnostic accuracy.
New PET-tracers, including 11C-methionine, 18-fluorothymidine (FLT) and 18 F-
misonidazole (FMISO) that target more specific tumour binding sites compared to
FDG, are developed in order to improve specificity in tumour detection or treatment
follow-up or to visualise specific prognostic tumour characteristics. While FMISO-
PET may hold important prognostic information pre-treatment by depicting tumour
hypoxia associated with treatment resistance, 11C-methionine and FLT may be used
for more specific tumour depiction and early response assessment. Functional MRI
sequences are developed aiming to improve lesion characterisation, nodal staging
and treatment follow-up. Most frequently used techniques are diffusion-weighted
MRI (DWI), dynamic-contrast-enhanced MRI (DCE-MRI) and MRI-spectroscopy
(MRS). Although MRS may have value in nodal staging and treatment assessment,
currently its main disadvantage is the limited spatial resolution. DWI measures
differences in water mobility between different tissue microstructures quantified
by the apparent diffusion coefficient, while DCE-MRI measures tissue perfusion
using permeability measurements or semi-quantitative perfusion parameters.
DWI is researched and gradually clinically implemented for locoregional staging,
differentiation of tumour recurrence from post-treatment complication and early
treatment follow-up. DCE-MRI mainly shows additional value for early assessment
of treatment response, but also as a prognostic imaging modality as pre-treatment
tumour perfusion may correlate with hypoxic status of the tumour.
Learning Objectives:
1. To understand the physiological basis and rationale for use of the different
and new functional imaging modalities and tracers in head and neck cancer.
2. To have an overview of the currently possible clinical applications and
compare the advantages and disadvantages of the different modalities for
pre and post-treatment imaging.
3. To have an overview of potential future applications for treatment prediction
and early treatment follow-up.
4. To recognise the potentially synergistic value between functional MRI
techniques and nuclear imaging techniques.
08:30 - 10:00 Room D2
Special Focus Session
SF 3d
Head and neck oncology: the three musketeers (CT,
MR, PET)
Moderator:
A. Borges; Lisbon/PT
A‑085 08:30
Chairman’s introduction
A. Borges; Lisbon/PT (
[email protected])
An increasing number of functional and metabolic imaging options reflecting relevant
aspects of tumour biology have rapidly been incorporated into clinical trials and, pro-
gressively, into clinical practice. While tumour staging according to the TNM system still
rules most decisions regarding treatment choice in head and neck cancer, biological
information from the tumour and its microenvironment has proven to have important
predictive and prognostic value heading for a tailored and individualised patient’s
management. CT, MR and PET are the mainstay imaging modalities to access tumour
extent, both of the primary tumour, lymphatic and distant metastases and for early
depiction of recurrence during patient’s follow-up. Hypoxia and angiogenesis, the
major driving forces for tumour aggressiveness, long linked to chemo and irradiation
treatment failure, can now be imaged both by PET (18 F-MISO or 60Cu ATSM) or
MRI (BOLD and PWI, respectively). This information is being used to define biological
tumour volumes, to tailor conformational and intensity modulated radiation treatments
and to select patients for specific treatments such as radiosensitizers, hypoxia selective
cytotoxic and antiangiogenic drugs. Overexpression/amplification of EGFR (epidermal
growth factor receptor) are common genetic abnormalities in SCC linked to increased
cell proliferation and worse prognosis. Imaging techniques reflecting cell proliferation/
density (18 F-FLT -desoxyfluorothymidine- and diffusion-weighted MRI) can be used
to select patients for treatment with EGFR inhibitors. This special focus session will
review the use of these imaging modalities both prior, during and after treatment of
head and neck cancer focusing on their specific advantages and accuracies in these
different settings.
Session Objectives:
1. To become familiar with the premises behind the choice of CT, MR and PET
in different anatomic areas of the head and neck.
2. To understand the added value of each technique in the diagnosis, follow-up
and prognostic prediction of head and neck cancer.
3. To be able to tailor an imaging protocol taking into account risk-benefit and
cost-effectiveness.
4. To become familiar with the clinical application of hybrid imaging and new
PET tracers.
A‑086 08:35
State-of-the-art CT/MR/PET as baseline modalities
S. Bisdas; Tübingen/DE (
[email protected]‑tuebingen.de)
Contrast-enhanced CT and MRI are routinely used in order to determine the precise
localisation, size and anatomic extent of the primary lesion. On the other hand,
positron emission tomography (PET) is the most sensitive and specific technique
for in vivo imaging of metabolic pathways and receptor-ligand interactions in the
tissues. A common question is which of these techniques should be used in a
particular patient. The most widely used technique is CT, as it has a number of
important advantages over MRI, like wide availability, relative low cost and short
examination time. However, CT also has a number of disadvantages compared to
MRI: relative low soft tissue contrast resolution, severe image quality degradation
by dental fillings or other metallic foreign objects, and radiation exposure. PET in
combination with CT and/or MRI has a good sensitivity and specificity for the de-
tection of primary tumour and for nodal staging as well as for detection in a single
examination distant metastases, occult tumours, second synchronous tumours, and
for radiotherapy planning. By combining PET with CT and MRI studies, either se-
quentially or synchronous performed, the diagnostic accuracy is significantly higher.
Learning Objectives:
1. To understand the advantages and shortcomings of each modality.
2. To learn the state-of-the-art CT/MR/PET protocols for routine imaging work-
up in head and neck.
3. To be able to select the appropriate modality for staging of head and neck
cancer according to the needs of the clinician and treatment planning.
Postgraduate.Educational.Programme
S28
A B C D E F G H
A‑091 09:30
C. Emergencies of non-gynaecologic origin
D. Akata; Ankara/TR (
[email protected])
During routine clinical practice, radiologist must often evaluate a wide range of cases
with acute abdominal and pelvic pain. Ultrasound (US) is the primary imaging modal-
ity of choice to evaluate pelvic pain in the female patient. Computed tomography
(CT) is mostly performed if ultrasound findings are equivocal or if the abnormality
extends beyond pelvis. Conditions such as appendicitis, diverticulitis, pyelonephritis
and renal calculi may develop in women of childbearing age with clinical features
that mimic obstetric and gynaecologic emergencies. Pelvic pain is a diagnostic
problem especially in pregnant woman. Ultrasound scanning has certain limitations
secondary to increasing gestational age. CT is not appropriate due to radiation dose.
In those situations, it has been proven that magnetic resonance (MR) imaging is a
valuable adjunct to delineate the pathology. In non-pregnant woman the radiological
evaluation is less difficult. Still, a multimodality approach may be needed in certain
cases. In this lecture, radiological features of non-gynaecologic emergencies such
as acute appendicitis, diverticulitis, renal calculi and pyelonephritis will be discussed.
Learning Objectives:
1. To understand the causes and imaging diagnosis of common non-
gynaecologic emergencies.
2. To recognise how these may mimic gynaecologic disease.
3. To understand the use of a multimodality approach to solve the problem.
08:30 - 10:00 Room E2
Foundation Course: Paediatric Radiology
E³ 320b
Genitourinary problems: common daily practice
Moderator:
V. Donoghue; Dublin/IE
A‑092 08:30
A. Imaging strategy in urinary infections
M. Riccabona; Graz/AT (
[email protected])
The purpose is to discuss the role of imaging and the potential of different methods
applicable in childhood UTI - with a focus on US. The imaging task in UTI has changed,
and new questions arouse for radiology. In addition, growing economical demands
pressurise radiology to restrict imaging to those conditions where an evident benefit
has been demonstrated. This efficacy-oriented approach is difficult in children due
to the lack of evidence-based data. Thus, controversies exist on if, when and how
to investigate childhood UTI, trying to minimise procedures and reduce burden on
children and health budgets without missing important conditions that may pose a
threat to the kidney. Furthermore, modern imaging with new methods, applications and
potential (e.g. contrast-enhanced voiding urosonography = ce-VUS) may influence
the imaging algorithm. Therefore, the clinical demand and the value of established as
well as new imaging for treatment have to be understood and balanced. Most of the
proposed imaging algorithms heavily relay on modern US including Doppler options,
recommend scintigraphy for the assessment of renal function and scarring, and define
the indications for MCU (or ce-VUS) from these findings, additionally considering
patient’s age, gender and presentation, with respect to the individual clinical context.
Imaging in childhood UTI has changed, some well-established methods and rules
persist. Basically, detection of renal involvement is the centre point of acute imaging,
with extended exploration, e.g. by MCU or MRI, in those who have complications,
scars/upper UTI, and other risk factors such as malformations.
Learning Objectives:
1. To learn about the role, the importance and the information obtained from
ultrasonography.
2. To learn about the technique and indications of voiding cystourethrography,
as well as the role and potential of nuclear medicine examinations.
3. To learn about an imaging algorithm for the imaging approach based on
existing ESUR & ESPR recommendations.
A‑093 09:00
B. Urinary tract dilatation: what should be done, to whom and when?
F.E. Avni; Brussels/BE (
[email protected])
The in utero and post-natal follow -up of foetuses with urinary tract dilatation has
provided lots of information about the proper management of urinary tract malforma-
tions. Nowadays, affected neonates are evaluated following standardised charts
Panel discussion:
The three musketeers were actually FOUR 09:44
CT, MR and PET: how to choose between modalities in head and neck cancer
patients. An increasing number of imaging modalities reflecting functional and
metabolic aspects of tumours have rapidly been incorporated into clinical practice.
These modalities provide additional information on tumour vascularisation/ angio-
genesis (CT and MR perfusion); on tumour metabolism, hypoxia and proliferation
(PET using different radioactively labelled substances) and on tumour architecture
and cellular density (DWI). Hybrid imaging, PET-CT and, in the near future PET-MR,
can provide morphologic, metabolic and functional information in a one-stop-shop
examination. The choice of the best modality (ies) to answer specific questions
in the diagnosis, follow -up and in the prediction of response to treatment and
prognosis will be addressed.
08:30 - 10:00 Room E1
Genitourinary
RC 307
Gynaecologic emergency and its mimics
Moderator:
K. Kinkel; Chêne‑Bougeries/CH
A‑089 08:30
A. Imaging of emergencies in pregnancy
G. Masselli; Rome/IT (
[email protected])
Acute abdominal and pelvic pain in pregnant women may be the manifestation of various
gynaecological and non-gynaecological conditions. The correct diagnosis of the causes
of acute pain during pregnancy is critical to minimise maternal-foetal morbidity and
mortality. Although ultrasound (US) is the primary imaging investigation in the diagnostic
evaluation of the pregnant patient, the role of magnetic resonance (MR) imaging in the
evaluation of foetal and maternal diseases in pregnant patients continues to expand.
MR imaging offers different potential advantages in comparison to US for evaluating
acute abdominal and pelvic pain; these include multiplanar imaging capabilities, a
higher soft tissue contrast and the ability to detect and distinguish blood from other
fluid collections. When US is equivocal or nondiagnostic, MR imaging is a valuable
complement to determine the exact aetiology of acute abdominal pain. The intrinsic
safety and the accuracy of MRI in diagnosing abdominal and pelvic disease make it an
excellent choice for triage of pregnant patients with acute abdominal and pelvic pain.
MR imaging provides important information that influences patient management, and it
is important for the radiologist to recognise the MR imaging appearance of the common
causes of acute abdominal and pelvic pain during pregnancy. This lecture will discuss
the use of MR imaging for maternal diseases that cause acute abdominal and pelvic
pain during pregnancy. Moreover, this lecture will discuss the different MR imaging
techniques to use, and will show how to detect and to differentiate the gynaecologic
and non-gynaecologic causes of pain during pregnancy.
Learning Objectives:
1. To learn the most common causes of gynaecologic pain in pregnancy.
2. To understand how to diagnose non-gynaecologic causes of pain in
pregnancy.
A‑090 09:00
B. Emergencies of gynaecologic origin
A.G. Rockall; London/UK (
[email protected])
In this lecture, the role of imaging in the evaluation of gynaecologic emergencies
will be presented. A combined approach using both clinical findings and imaging
features is necessary. Accurate evaluation is important as failure to make a diagno-
sis may lead to serious consequences. Presenting symptoms, such as pelvic pain
or vaginal bleeding or discharge, may overlap with pregnancy-related emergencies
and with non-gynaecologic abdominal emergencies. The range of conditions to be
considered include ovarian cyst emergencies (cyst rupture, haemorrhage or torsion),
infective conditions (Bartholins’ or vulval abscess, pelvic inflammatory disease or
tubo-ovarian abcess) and acute bleeding (from inflammation, neoplasm, or trauma).
Pain may be related to the menstrual cycle, as in endometriosis or ruptured corpus
luteum, or may be unrelated, such as in fibroid or ovarian torsion or pelvic inflam-
matory disease. The imaging features of these acute abnormalities will be reviewed
and discussed in the context of the differential diagnoses.
Learning Objectives:
1. To understand the causes of common gynaecologic emergencies.
2. To understand the imaging diagnosis of common gynaecologic emergencies.
Friday
Postgraduate.Educational.Programme
A
S29
CB D E F G H
the choice of b-factors on WB-MRI will all be analysed. Emerging applications of
WB-MRI and of WB-DWI will be exposed, especially regarding onco-haematological
malignancies. WB-MRI can allow combination of morphologic and functional data
on a whole body scale. Optimisation of MR instrumentation, standardisation of MR
protocols and future studies on specific diseases are under way.
Learning Objectives:
1. To understand the technical specificities of whole body DWI.
2. To know how to apply whole body DWI in the detection and functional
assessment of tumours, including haematological malignancies.
3. To learn about the developments of whole body DWI for tumour staging and
response assessment.
A‑096 09:00
B. Quality and quality control in DCE-MRI and DCE-CT
V.J. Goh; Northwood/UK (
[email protected])
Dynamic contrast enhanced MRI and CT provide valuable information of the anti-
vascular effect of anti-angiogenic and vascular disruptive agents. The quality of
DCE-MRI or DCE-CT data is influenced by patient, acquisition and post-processing
factors. For example, patient habitus, scanner type, acquisition parameters, contrast
agent and administration profile, signal to noise, input function, kinetic model, and
processing software affect the accuracy of quantification. Multisite acquisition and
processing provide challenges to multicentre implementation of DCE techniques
within and outside the context of clinical trials: standardised acquisition and process-
ing on the same scanner and software platform, while ideal may not be possible.
Quality control is essential to maintain accuracy and consistency of standards
across all sites. A consensus-based, practical approach to quality control of DCE-
MRI and CT in early phase clinical trials will be presented.
Learning Objectives:
1. To understand the differences obtained with different imaging techniques.
2. To understand the differences obtained with different processing software.
3. To know the limitations of multi-site acquisition or processing.
A‑097 09:30
C. Synthesis: functional imaging for tumour management
V. Vilgrain; Clichy/FR (
[email protected])
The major functional imaging tools for tumour management are obtained with
dynamic contrast-enhanced imaging, diffusion-weighted MR imaging, and MR
elastography. These acquisitions allow understanding of tumour angiogenesis
and perfusion, and tumour architecture. Dynamic contrast material-enhanced
imaging allows assessment of perfusion parameters. Diffusion-weighted MR
imaging provides information that reflects tissue cellularity and the integrity of
cellular membranes. MR elastography evaluates the mechanical properties of
tissue such as stiffness and viscosity. To date, tumour detection is mainly based
on morphologic features. However, changes in perfusion parameters have been
shown as early parameters of liver metastases detection in patient with colorectal
carcinoma or breast carcinoma. Tumour characterisation is usually based on mor-
phologic features. Yet, perfusion parameters have been shown to correlate with
microvascular density and tumour differentiation helping tumour characterisation.
Furthermore, apparent coefficient diffusion (diffusion-weighted MR imaging) and
stiffness and viscosity (MR elastography) are significantly different in benign and
malignant tumours. Despite these differences, these last parameters usually do
not allow definitive subtyping. Functional imaging starts playing a major role in
non-surgical treatment follow-up especially with targeted cancer therapy. Changes
in perfusion parameters, apparent coefficient diffusion, and stiffness and viscosity
are observed in responders. Interestingly, these changes appear promptly after
treatment initiation. These functional variables are not included in RECIST 1.1 but
might be part of response criteria in the next future. Many examples of functional
imaging for tumour management will be provided.
Learning Objectives:
1. To understand the potential of functional imaging in tumour detection.
2. To understand the potential of functional imaging in tumour characterisation.
3. To learn about the future use of functional imaging in treatment planning and
follow-up.
(among others, thanks to the ESUR-ESPR working group). At birth, a confirmatory
ultrasound is performed in order to evaluate the type and degree of the malforma-
tion. Urinary tract dilatation are separated into mild, moderate and marked. Mild
and moderate dilatation will be followed by US. Voiding cystogram and functional
studies will be performed only if the dilatation is significant or persists. The prog-
nosis is usually good. Patients with marked dilatation would be managed more
“aggressively”. Their work-up would be initiated as soon as diagnosed in order to
diagnose cases that need therapeutic manoeuvre. For them voiding cystogram,
anatomical and functional studies cannot be skipped and are important for the
prognosis. Long-term follow-up are needed to prevent further damage.
Learning Objectives:
1. To learn which infants with antenatal diagnosis of urinary tract dilatation
require imaging and when.
2. To become familiar with the most important differential diagnosis.
3. To learn about the imaging strategies in these infants.
A‑094 09:30
C. Renal and pararenal masses: basic rules
P. Tomà; Rome/IT (
[email protected])
The differential diagnosis of renal and pararenal masses firstly depends on the
age of the child. Wilms tumour (nephroblastoma) is the most common abdominal
tumour in 1-8 years old (80% of cases in children less than 5 years old - peak age
3.6 years). Renal non-Wilms tumours represent a significant proportion of renal
tumours in children, especially in children aged less than 6 months or greater than
12 years. Neuroblastoma most commonly arises from the adrenal gland but can
arise anywhere along sympathetic chain; it is the most common tumour in children
under 2 years of age (90% of cases in children less than 5 years - mean age < 2
years). Adrenal adenomas and carcinomas also occur in childhood. US is the initial
imaging modality to investigate an abdominal mass in children. CT or MRI is used
to confirm the US findings and not uncommonly add new, valuable information.
Concerning Wilms tumour there is a very diverse approach to treatment according
to geographical location. This variation in therapeutic attitude has consequences
for the choice of imaging modality at diagnosis. Neuroblastoma staging includes
also 123I-MIBG, and laboratory investigations (bilateral bone marrow aspirates with
histochemical tests and urine catecholamine level measurements). We focus on
the points under discussion: revision to the staging of neuroblastoma, the problems
inherent in distinguishing nephrogenic rests from Wilms tumour and the approach
regarding small lung nodules in children with Wilms tumour.
Learning Objectives:
1. To understand the imaging findings of paediatric renal and pararenal
masses.
2. To learn how and when to use sonography, CT and MRI in investigation and
differential diagnosis.
3. To learn about the role of imaging in staging renal and pararenal
malignancies.
08:30 - 10:00 Room F1
Functional Imaging of Tumours: How to do it
MC 322
Functional and ultra structural MR
Moderator:
L. Martí‑Bonmatí; Valencia/ES
A‑095 08:30
A. Diffusion imaging and whole body MRI
A. Luciani, C. Lin, F. Pigneur, C. Haioun, E. Itti, A. Rahmouni; Creteil/FR
It is now well accepted that treatment strategies and patients prognosis rely in
large part on initial tumour staging. Early response assessment in cancer patients
further enables adapted treatment selection treatment response on imaging. Recent
instrumentation MR developments, including routine high field imaging, phased
array coils and parallel imaging bring whole body MR imaging to clinical practice.
Moreover, both optimised morphologic imaging and functional data previously
obtained on specific dedicated examinations can be provided on a whole body
scale. The aim of this lecture will be to review technical requirements of whole
body MR imaging, with special focus on dynamic contrast-enhanced MRI (DCE-
MRI), diffusion weighted imaging on a whole body scale (WB-DWI), and MRI us-
ing continuous rolling platform. The combination of phased array coils, enabling
parallel acquisitions, the selection of dynamic contrast enhanced sequences, and
Postgraduate.Educational.Programme
S30
A B C D E F G H
A‑100 08:58
Decreasing the number of BI-RADS 3 in clinical settings
L.J. Pina Insausti; Pamplona/ES (
[email protected])
It is important to minimise the number of lesions classified as BI-RADS 3. In a clinical
setting we can support our diagnoses using more additional imaging techniques
than in a screening setting. The ways to decrease the BI-RADS 3 lesions are as
follows. 1. Careful review of previous imaging studies: if the lesion had a benign
appearance and was seen on previous studies, it should be classified as BI-RADS
2. 2. Palpation: the physical examination may be crucial to classify a lesion. 3.
History of breast cancer and other clinical conditions: BI-RADS category 3 should
be avoided as much as possible for BRCA carriers, patients having a recently
diagnosed breast cancer or if pregnancy is planned. 4. Radiologist’s experience:
unexperienced radiologists tend to use more of this category. 5. Complementary
studies: spot compressions and magnifications views can show suspicious signs
that were not detected on conventional views, upgrading to BI-RADS 4 or 5. US
can classify a mass as a cyst (category 2). Sonoelastography can also play a role.
Very high spatial resolution breast MRI can be useful to evaluate the margins of
the lesion more accurately, upgrading the lesion to category 4 or 5. 6. Size of the
lesion: an important requirement to choose follow-up for a probably benign lesion
is to ensure that, in case of being a malignant lesion, it will be an early diagnosis.
Finally, the patient’s age is important: the typical appearance of a benign lesion in
a young low-risk woman (< 30) can make unnecessary periodic follow-up.
Learning Objectives:
1. To appreciate the reasons for inconsistency of cancer incidence between
published studies.
2. To understand the difficulties of using some of the specific descriptors and
their current limitations.
3. To become familiar with the way to integrate imaging modalities to reduce
uncertainty.
4. To recognise the influence of clinical data in the management of a BI-RADS
3 lesion.
A‑101 09:21
Management of BI-RADS 3 lesions
F. Sardanelli; Milan/IT (
[email protected])
The principle of BI-RADS 3 imaging finding should be that of “quasi-benign” type,
i.e. with a very low associated risk of malignancy (< 2%), opening the possibility of
a short-term imaging follow-up as an alternative to imaging-guided needle biopsy.
However, a number of issues should be regarded as relevant to radiologists and
patients. 1. BI-RADS 3 cancer prevalence is highly variable due to (1.1) different
prevalence in the study population (symptomatic/asymptomatic, clinical/screening
setting; high-risk [BRCA1, BRCA2, family history, etc.], intermediate risk [dense
breasts; previous breast cancer or high-risk lesions], relatively low risk) and/or
(1.2) radiologists' differences in classification. 2. When needle biopsy is optioned,
vacuum-assisted biopsy under stereotactical guidance for mammographic only
findings (typically, microcalcifications) and core-biopsy for sonographic findings
should be used; fine needle aspiration cytology should be avoided due to the high
probability of benign lesions which need larger tissue samples. 3. When short-term
follow-up (typically, 6 months) is optioned, the same technique on which the BI-
RADS 3 lesions was initially detected should be used. 4. In the screening setting,
short-term follow-up option is commonly not considered and the reader is forced to
give a dichotomic reading (recall/not recall). 5. The choice between the two options
should be clearly discussed with the patient, including the psychological cost of
waiting six months to get a conclusive report, and a really informed consent should
be obtained. 6. Till now, there is insufficient evidence for using tomosynthesis or
MRI for evaluating mammographic or sonographic BI-RADS 3 findings.
Learning Objectives:
1. To learn about the management options of a BI-RADS 3 lesion.
2. To appreciate the costs to the patient of different management options.
3. To appreciate the costs to the organisation of different management options.
Panel discussion:
BI-RADS 3: biopsy or watch? 09:44
The premise behind the BI-RADS 3 classification is to identify a group of low risk
lesions that can be safely placed on follow -up rather than biopsy. In practice this
can be very difficult and is anachronistic to the principles of the European population
screening programmes where the radiology objective is to diagnose or discharge.
The panel will discuss these dilemmas.
08:30 - 10:00 Room F2
Special Focus Session
SF 3a
The BI-RADS 3 controversy
Moderator:
M.G. Wallis; Cambridge/UK
A‑098 08:30
Chairman’s introduction
M.G. Wallis; Cambridge/UK (
[email protected])
Starting in the late 1980s an American College of Radiologists task force developed
the concept of guidelines to standardise mammography reporting: breast imag-
ing reporting and data system (BI-RADS). There is evidence that over time there
have been improvements in consistency of use, sensitivity, specificity and positive
predictive value. However, BI-RADS 3 ‘probably benign; short interval follow -up
recommended; less than 2% risk of malignancy’ has always been the most difficult
and controversial, with the highest levels of discordance between classification and
recommendation, wide variation in both intra- and inter-observer agreement and
a 2007 literature review demonstrating PPV for malignancy of between 0 and 8%.
Management of breast disease has moved on a great deal since the 1990s. In
the main driven by increasing specialisation associated with population screening
programmes. Nowadays a specialist breast radiologist works with a wide variety of
needle options at his hip to such an extent that the breast Multi-Disciplinary Team
increasingly feels that failure to obtain a non-operative diagnosis of discrete lesions
is unacceptable. In this setting, and mindful of the medico legal consequences of
‘delayed diagnosis’, is there still room to allow a patient to leave the one stop clinic
without a definitive diagnosis? As the leaders of the diagnostic team we also have
to take account of the emotional and psycho-social consequences for our patients
as well as the financial costs to patient and the healthcare economy.
Session Objectives:
1. To consolidate knowledge of BI-RADS classification with respect to grade 3.
2. To appreciate the potential variability in interpretation of BI-RADS 3.
3. To appreciate the management options and their implications for both patient
and organisation.
A‑099 08:35
Defining lesions to follow-up
P. Skaane; Oslo/NO (
[email protected])
Breast imaging reporting and data system (BI-RADS) was developed for standardis-
ing reporting and include mammography, ultrasound, and MRI. BI-RADS category 3
“probably benign finding - short-interval follow-up suggested” should have less than
2% risk of malignancy. Category 4 has been subgrouped into 4 A, 4B, and 4C, and
this influence the classification of BI-RADS 3. Mammographic BI-RADS 3: three
nonpalpable findings in this category include clusters of punctate microcalcifica -
tions, well-circumscribed and noncalcified solitary masses, and benign-appearing
asymmetric density. Digital mammography will increase detection of amorphous
microcalcifications and the number of BI-RADS 3 (or 4 A) lesions. Intramammary
lymph nodes and calcified fibroadenomas are BI-RADS 2 lesions. Ultrasonographic
BI-RADS 3: a most important BI-RADS 3 lesion is a solid oval mass (“tumour”)
with gently lobulations, circumscribed margins, and parallel orientation. Using strict
criteria, the negative predictive value is approaching 99%. Two other lesions are
nonpalpable “complicated cyst” and clustered microcysts. The “complex” cyst, i.e.,
a mass with cystic and solid components, should be classified as BI-RADS 4. MRI
BI-RADS 3: there is lack of evidence which MRI findings should be categorised
BI-RADS 3. Nonmass-like enhancement (NMLE) and enhancement kinetics are
unique to MRI. Lesions less than 5 mm (“foci”) need no assessment. A challenge is
MRI-detected tumours < 10 mm as morphologic analysis is of limited value. Benign
kinetic curves may justify short-term follow -up. In high-risk women, MRI-guided
vacuum-assisted biopsy should be considered. In conclusion, BI-RADS 3 is justified
in diagnostic settings but should be avoided or kept at a minimum in screening.
Learning Objectives:
1. To understand the mammography features of BI-RADS 3 classification.
2. To understand the ultrasound features of BI-RADS 3 classification.
3. To understand the MRI features of BI-RADS 3 classification.
Friday
Postgraduate.Educational.Programme
A
S31
CB D E F G H
08:30 - 10:00 Room G/H
New Horizons Session
NH 3
Quantum leaps in MRI: teslas, pulses, tracers
Moderator:
O. Clément; Paris/FR
A‑102 08:30
Chairman’s introduction
O. Clément; Paris/FR (
[email protected])
What will be the routine MR machine in 10 years? Which field strength? Which
coils? Which gradient design? Which contrast agents? Which combination will
allow a gain in sensitivity to allow molecular imaging? Can hybrid imaging be a
solution? The goal of this session is to review the technical developments in field
strength, pulse, RF coils and contrast agents, and to discuss the necessary choices
for future MR scans.
Session Objectives:
1. To review the different perspectives of progress in MRI.
2. To understand that the progress is both instrumental and chemical with new
probes.
3. To envisage a scenario where MRI will offer molecular imaging capacities.
A‑103 08:35
What will be the standard machine and field of the future?
L. Darrasse; Orsay/FR (luc.darrasse@u‑psud.fr)
Improving the sensitivity has still been an essential issue in MRI, because the signal
from nuclear spins relies on extremely weak magnetic interactions dominated by thermal
fluctuation. To push the signal-to-noise ratio upward, the basic routes have been (i) to
increase the field strength, (ii) to improve the signal detection with radiofrequency coils
and (iii) to enhance the signal dynamically with contrast agents or alternative preparation
techniques. The first route is the most obvious one, driven by the trends in analytical
MR spectroscopy and small-animal MRI. Going up to or even above 7 T represents a
considerable challenge, both technically and in view to renew the MR equipment market.
However, this way is limited by safety issues, radiofrequency penetration concerns
and susceptibility artefacts. Alternatively, improving the radiofrequency system relies
on a complex electrodynamics background, where tissue conductivity and different
sources of noise have to be considered. During the last half-period of MRI development,
radiofrequency coil arrays have appeared as a powerful mean to improve the signal-
to-noise and to accelerate the spatial encoding process, even able to overcome some
pitfalls with high-field MRI. Finally, the topics of an optimal field strength has always
been highly controversial because the contrast mechanisms, on which the diagnostic
information is mainly founded, are essentially field-dependent. Basically, the contrast
mechanisms tend to be dominated, respectively, by macromolecular cross-relaxation
at low field, and by susceptibility-weighted diffusion at high field. An emerging ques-
tion is then to address different pathologies or organs with either general-purpose or
dedicated MRI systems.
Learning Objectives:
1. To learn about the possibilities of gaining a jump in signal.
2. To understand the respective strategies of field increase and coil
improvements.
3. To consider the probable system in 2020.
A‑104 08:58
Will new technologies allow a jump in sensitivity?
J. Hennig; Freiburg/DE (Juergen.Hennig@uniklinik‑freiburg.de)
Imaging technologies have made breathtaking progress for several decades and
in all aspects of medical imaging - MR, CT, US and PET. Amongst the current
developments in MRI there are several areas which hold promise to redefine the
boundaries of sensitivity. Ultrahighfield MRI with field strengths of 7 T and more
starts to reveal insights into tissue microstructure so far inaccessible to MR (or
any other technique). This is still under intense technological development with
some key issues to resolve notably safety issues related to the high radiofrequency
power. The unique contrast and resolution does hold promise for highly relevant
applications such as neurodegenerative disease, small vessel disease, MS and
others - although definite clinical studies for a ‚killer application‘ are still lacking.
13C-Hyperpolarisation of metabolites such as pyruvate, succinate, bicarbonate,
etc. lead to an increase in detection sensitivity by factors of 10-100,000. Finally, the
development of targeted probes is progressing extremely rapidly and for all imaging
modalities. Most of this work is aimed at preclinical research, but the tremendous
impact of the new insight in translational research promises to be of high impact
for clinical application. Will these technologies allow a jump in sensitivity? Yes and
no. Image quality, contrast and sensitivity will grow significantly. The biggest impact
will, however, lie in the combination of the new possibilities with other data - imag-
ing as well as non-imaging. A true change in paradigm will only be achieved if the
current parcellated knowledge about various aspects of the disease is unified into
a comprehensive picture.
Learning Objectives:
1. To review the recent developments in RF-coils and gradients.
2. To learn about the new measurements technologies.
3. To envision how these new tools will allow a huge gain in sensitivity.
A‑105 09:21
Will new MR contrast probes compete with PET?
S. Aime; Turin/IT (
[email protected])
Purpose: Molecular imaging is a new science that will have a tremendous impact
in the development of innovative diagnostic tools. In the first stage of its enrolment,
it has relied massively on PET/SPECT and optical imaging technologies because of
the superior sensitivity of their probes. In the long-term, MRI/MRS approaches may
recover a central role, provided that further sensitivity improvements will be attained.